Photo from pink.citeline.com
Jul 14, 2024, 22:08
Ivan R. Gonzalez: Project Orbis: A global initiative to accelerate the review of cancer drugs in the US, Canada, and the UK
Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X:
”Project Orbis: A global initiative to accelerate the review of cancer drugs in the US, Canada, and the UK (2019-2023) reveals:
- 33% of FDA approvals through Orbis.
- Overall survival: 4.1 months (Orbis) vs. 2.7 months (others).
- Reimbursements: 100% (Scotland), 40% (England), 90% (Canada, conditional).
- Access times significantly increased.
- Average monthly cost: $20,000 USD.
Spending on medications surpasses the rate of new cases. It’s crucial to evaluate benefits and costs for a comprehensive global health impact. Project Orbis is expanding, but a deeper understanding of its implications is needed.”
Source: Ivan R. Gonzalez/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 09:31
Nov 14, 2024, 09:26
Nov 14, 2024, 09:21
Nov 14, 2024, 09:15
Nov 14, 2024, 00:19